Literature DB >> 16542813

Enterotoxigenic Escherichia coli colonization factor types collected from 1997 to 2001 in US military personnel during operation Bright Star in northern Egypt.

David M Rockabrand1, Hind I Shaheen, Sami B Khalil, Leonard F Peruski, Patrick J Rozmajzl, Stephen J Savarino, Marshall R Monteville, Robert W Frenck, Ann-Mari Svennerholm, Shannon D Putnam, John W Sanders.   

Abstract

Operation Bright Star (OBS) is a biennial, multinational exercise in Egypt involving 15000 US troops. Consistent with past observations in deployed troops, diarrhea is the most significant cause of morbidity. Focused efforts are ongoing to develop vaccines against the most common pathogens affecting our troops. As part of these efforts, diarrhea surveillance was conducted during OBS to monitor pathogens associated with illness and to identify new vaccine targets. A retrospective review was conducted of prior studies with similar methods. Soldiers with diarrhea presenting to the OBS clinic provided a stool sample that was inoculated into Carey-Blair transport media. Within 3 days, the Cary-Blair tubes were transported to the Naval Medical Research Unit no. 3 in Cairo where bacterial culture was performed. As part of the evaluation, 5 Escherichia coli-like colonies were collected and tested for toxin production using the GM1-ELISA. Toxin-positive isolates were further tested for colonization factors (CF) by a dot-blot assay using a standardized panel of monoclonal antibodies against CFA/I, CS1-CS7, CS17, CS8 (CFA/III), CS12 (PCFO159), and CS14 (PCFO166). Enterotoxigenic E. coli (ETEC) was the most frequently isolated pathogen during each OBS from which data were collected. The rate of ETEC-associated diarrhea ranged from 22% to 58%. Over time, there were dramatic shifts in the frequency and distribution of CFs. Over the 5 years of study, an increasing number of ETEC isolates had no known CF identified, and in 2001, only 40% of ETEC was associated with known CFs. The most commonly identified CF was CS6. Diarrheal disease, particularly ETEC, continues to be a common malady among US military personnel deployed to Egypt. We have identified ETEC CF types, especially CS6, which should be considered potential vaccine candidates. However, despite intensive testing, CFs could not be identified in most of the ETEC isolated, highlighting the need for further studies to identify novel CFs and alternative vaccine targets.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16542813     DOI: 10.1016/j.diagmicrobio.2005.12.002

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  11 in total

1.  Global Infectious Disease Surveillance at DoD Overseas Laboratories, 1999-2007.

Authors:  J Jeremy Sueker; Jean-Paul Chretien; Joel C Gaydos; Kevin L Russell
Journal:  Am J Trop Med Hyg       Date:  2010-01       Impact factor: 2.345

2.  Mucosal and systemic immune responses in patients with diarrhea due to CS6-expressing enterotoxigenic Escherichia coli.

Authors:  Firdausi Qadri; Tanvir Ahmed; Firoz Ahmed; M Saruar Bhuiyan; Mohammad Golam Mostofa; Frederick J Cassels; Anna Helander; Ann-Mari Svennerholm
Journal:  Infect Immun       Date:  2007-02-12       Impact factor: 3.441

3.  Confronting challenges to enterotoxigenic Escherichia coli vaccine development.

Authors:  James M Fleckenstein
Journal:  Front Trop Dis       Date:  2021-09-24

4.  Characterization and studies of the cellular interaction of native colonization factor CS6 purified from a clinical isolate of enterotoxigenic Escherichia coli.

Authors:  Abhisek Ghosal; Rudra Bhowmick; Rajat Banerjee; Sandipan Ganguly; S Yamasaki; T Ramamurthy; T Hamabata; Nabendu Sekhar Chatterjee
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

5.  Overcoming Enterotoxigenic Escherichia coli Pathogen Diversity: Translational Molecular Approaches to Inform Vaccine Design.

Authors:  James M Fleckenstein; David A Rasko
Journal:  Methods Mol Biol       Date:  2016

6.  Hotel clinic-based diarrheal and respiratory disease surveillance in U.S. service members participating in Operation Bright Star in Egypt, 2009.

Authors:  Peter J Sebeny; Isabelle Nakhla; Manal Moustafa; Jody A Bruton; Joanne Cline; Douglas Hawk; Hanan El-Mohammady; Rania A Nada; Salwa F Ahmed; Guillermo Pimentel; Sylvia Y N Young
Journal:  Am J Trop Med Hyg       Date:  2012-08       Impact factor: 2.345

7.  Comparative analyses of phenotypic and genotypic methods for detection of enterotoxigenic Escherichia coli toxins and colonization factors.

Authors:  A Sjöling; G Wiklund; S J Savarino; D I Cohen; A-M Svennerholm
Journal:  J Clin Microbiol       Date:  2007-08-08       Impact factor: 5.948

Review 8.  Enteric disease surveillance under the AFHSC-GEIS: current efforts, landscape analysis and vision forward.

Authors:  Nisha N Money; Ryan C Maves; Peter Sebeny; Matthew R Kasper; Mark S Riddle; Max Wu; James E Lee; David Schnabel; Robert Bowden; Edwin V Oaks; Victor Ocaña; Luis Acosta; Eduardo Gotuzzo; Claudio Lanata; Theresa Ochoa; Nicolás Aguayo; Maruja Bernal; Rina Meza; Enrique Canal; Michael Gregory; David Cepeda; Erlin Listiyaningsih; Shannon D Putnam; Sylvia Young; Adel Mansour; Isabelle Nakhla; Manal Moustafa; Khaled Hassan; John Klena; Jody Bruton; Hind Shaheen; Sami Farid; Salwa Fouad; Hanan El-Mohamady; Timothy Styles; L C D R Danny Shiau; Benjamin Espinosa; Kellie McMullen; Eva Reed; Donald Neil; Doug Searles; Remington Nevin; Annette Von Thun; Cecili Sessions
Journal:  BMC Public Health       Date:  2011-03-04       Impact factor: 3.295

Review 9.  Tailoring the Immune Response via Customization of Pathogen Gene Expression.

Authors:  Lisa M Runco; Charles B Stauft; J Robert Coleman
Journal:  J Pathog       Date:  2014-02-25

10.  Phenotypic and genotypic analysis of enterotoxigenic Escherichia coli in samples obtained from Egyptian children presenting to referral hospitals.

Authors:  H I Shaheen; I A Abdel Messih; J D Klena; A Mansour; Z El-Wakkeel; T F Wierzba; J W Sanders; S B Khalil; D M Rockabrand; M R Monteville; P J Rozmajzl; A M Svennerholm; R W Frenck
Journal:  J Clin Microbiol       Date:  2008-10-29       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.